DEPOMED WKN: A2N4B9 ISIN: US04545L1070 Kürzel: ASRT Forum: Aktien Thema: Hauptdiskussion
0,745 EUR
+2,05 %+0,015
20. May, 09:58:22 Uhr,
Lang & Schwarz
Kommentare 98
Chemical,
15.02.2020 8:29 Uhr
0
Assertio Therapeutics: A Biotech Stock Trading Below Its Cash Balance
https://seekingalpha.com/article/4324469-assertio-therapeutics-biotech-stock-trading-below-cash-balance
Takeaway
ASRT has seen its fair share of woes, from the recent rejection of its cosyntropin sNDA, to below-average data readout on collaboration project IW-3718, and to a staggering -20% Y/Y decline on core product revenues. On the other hand, the recent sale of Nucynta for $375M removes all remaining debt from the company's balance sheet, causes its stock to trade at negative enterprise value, and adds sizable capital for future R&D efforts. Keep in mind, ASRT is estimated to continue its profitability after the deal closes, as its remaining products have over 60-80% gross margin. Hence, the author finds the benefit to outweigh the company's drawbacks, and will reiterate the company's buy rating as of today.
Chemical,
11.05.2020 14:44 Uhr
0
Assertio Therapeutics EPS beats by $0.18, beats on revenue https://seekingalpha.com/news/3572647-assertio-therapeutics-eps-beats-0_18-beats-on-revenue
Chemical,
06.02.2020 22:04 Uhr
0
Assertio Therapeutics Announces Sale of NUCYNTA® Franchise to Collegium Pharmaceutical for $375.0 Million
https://newsfilter.io/a/3d0fa5d5f5e45ad603002142755aedb8
Chemical,
13.01.2020 14:20 Uhr
0
Assertio Therapeutics Sees FY19 Neurology Franchise Sales Above Guidance Range Of $102M-$105M
Chemical,
13.01.2020 14:19 Uhr
0
Assertio Therapeutics Announces Closing Of Gralise Sale To Alvogen; Co. To Receive $127.5M
Chemical,
28.12.2019 14:28 Uhr
0
Assertio pipeline products
https://www.assertiotx.com/products-and-pipeline/pipeline/
Zwei Medikamente stehen vor dem Approvel
Chemical,
27.12.2019 20:28 Uhr
0
Assertio (ASRT) Upgraded to Strong Buy: What Does It Mean for the Stock?
https://finance.yahoo.com/news/assertio-asrt-upgraded-strong-buy-170005299.html
The upgrade of Assertio to a Zacks Rank #1 positions it in the top 5% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.
Chemical,
27.12.2019 20:26 Uhr
0
ASRT vs. PCRX: Which Stock Is the Better Value Option?
https://finance.yahoo.com/news/asrt-vs-pcrx-stock-better-164004569.html
ASRT sticks out from PCRX in both our Zacks Rank and Style Scores models, so value investors will likely feel that ASRT is the better option right now
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | News - InnoCan Pharma Aktie | +0,78 % | |
2 | WHIRLPOOL Hauptdiskussion | -0,37 % | |
3 | Cherry Hauptdiskussion | +14,05 % | |
4 | WACKER CHEMIE Hauptdiskussion | -3,21 % | |
5 | PAG911 | -0,24 % | |
6 | Forum für Leute, die wirklich Interesse an Intellabridge (Kash 2.0) haben! | -9,46 % | |
7 | RIO TINTO Hauptdiskussion | -0,24 % | |
8 | DERICHEBOURG Hauptdiskussion | -0,51 % | |
9 | SHELL Hauptdiskussion | -0,16 % | |
10 | Discovery (A) | -2,17 % | Alle Diskussionen |
Anzeige
Aktien
|
Thema | ||
---|---|---|---|
1 | News - InnoCan Pharma Aktie | +0,78 % | |
2 | WHIRLPOOL Hauptdiskussion | -0,37 % | |
3 | Cherry Hauptdiskussion | +14,05 % | |
4 | WACKER CHEMIE Hauptdiskussion | -3,21 % | |
5 | PAG911 | -0,24 % | |
6 | Forum für Leute, die wirklich Interesse an Intellabridge (Kash 2.0) haben! | -9,46 % | |
7 | RIO TINTO Hauptdiskussion | -0,24 % | |
8 | DERICHEBOURG Hauptdiskussion | -0,51 % | |
9 | SHELL Hauptdiskussion | -0,16 % | |
10 | Discovery (A) | -2,17 % | Alle Diskussionen |